| Methods |
Design:
randomised, placebo‐ controlled, double‐blind
parallel groups
4 months |
| Participants |
Country: U.S.A.
n=42 (36 completers) probable AD (NINCDS), mild dementia (MMSE 10‐26). Aged 78 (SD 1). Mix natural and surgical menopause. Exclusion criteria: Contra‐ indications for HRT use, no use HRT or cognition enhancers last 3 months. |
| Interventions |
1. CEE oral 1.25 mg/day
2. Placebo |
| Outcomes |
General (ADAS‐Cog, BIMC)
Memory: (Paragraph recall, VRT, Digit Span), Speed: (TMT) Language (Naming, Token test) |
| Notes |
HRT > placebo on TMT‐B (wk 4), Placebo > HRT on VRT (wk 16), Paragraph recall + Digit span (wk 4), trend for reverse for both at wk 16
1/8 tests
Adverse events:
3 vaginal spotting |
